Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg H Waetzig

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Inflammatory Bowel Diseases|June 1, 2004
Mechanisms of infliximab: the reverse side of a drug effectGeorg H Waetzig, Stefan Schreiber
Expert Opinion on Therapeutic Targets|February 14, 2012
Hitting a complex target: an update on interleukin-6 trans-signallingGeorg H Waetzig, Stefan Rose-John
Gastroenterology|May 12, 2018
ReplyStefan Schreiber, Susanna Nikolaus, Georg H Waetzig, et al.
Nature Medicine|September 5, 2024
Cardiovascular safety of vitamin B<sub>3</sub> administrationStefan Schreiber, Georg H Waetzig, Matthias Laudes, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2026
Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infectionStefan Schreiber, Philip Rosenstiel, Stephan J Ott, et al.
Metabolism: Clinical and Experimental|June 1, 2020
Letter to the Editor: Non-specific effects resulting from use of tocilizumab in miceJuliane Lokau, Georg H Waetzig, Stefan Rose-John, et al.
Gastroenterology|August 2, 2003
Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximabGeorg H Waetzig, Philip Rosenstiel, Susanna Nikolaus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2002
p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel diseaseGeorg H Waetzig, Dirk Seegert, Philip Rosenstiel, et al.
Expert Opinion on Therapeutic Targets|May 1, 2007
The IL-6/sIL-6R complex as a novel target for therapeutic approachesStefan Rose-John, Georg H Waetzig, Jürgen Scheller, et al.
Biochemical and Biophysical Research Communications|September 22, 2012
Identification of structural traits that increase the antimicrobial activity of a chimeric peptide of human β-defensins 2 and 3Björn Spudy, Frank D Sönnichsen, Georg H Waetzig, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Inflammatory Bowel Diseases|June 1, 2004
Mechanisms of infliximab: the reverse side of a drug effectGeorg H Waetzig, Stefan Schreiber
Expert Opinion on Therapeutic Targets|February 14, 2012
Hitting a complex target: an update on interleukin-6 trans-signallingGeorg H Waetzig, Stefan Rose-John
Gastroenterology|May 12, 2018
ReplyStefan Schreiber, Susanna Nikolaus, Georg H Waetzig, et al.
Nature Medicine|September 5, 2024
Cardiovascular safety of vitamin B<sub>3</sub> administrationStefan Schreiber, Georg H Waetzig, Matthias Laudes, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2026
Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infectionStefan Schreiber, Philip Rosenstiel, Stephan J Ott, et al.
Metabolism: Clinical and Experimental|June 1, 2020
Letter to the Editor: Non-specific effects resulting from use of tocilizumab in miceJuliane Lokau, Georg H Waetzig, Stefan Rose-John, et al.
Gastroenterology|August 2, 2003
Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximabGeorg H Waetzig, Philip Rosenstiel, Susanna Nikolaus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2002
p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel diseaseGeorg H Waetzig, Dirk Seegert, Philip Rosenstiel, et al.
Expert Opinion on Therapeutic Targets|May 1, 2007
The IL-6/sIL-6R complex as a novel target for therapeutic approachesStefan Rose-John, Georg H Waetzig, Jürgen Scheller, et al.
Biochemical and Biophysical Research Communications|September 22, 2012
Identification of structural traits that increase the antimicrobial activity of a chimeric peptide of human β-defensins 2 and 3Björn Spudy, Frank D Sönnichsen, Georg H Waetzig, et al.
Pageof 6